ArticleMedicine2026
Assessing the albumin-bilirubin score's role in predicting the mortality rate of severe acute pancreatitis: A multicenter retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The albumin-bilirubin (ALBI) score serves as an effective alternative for assessing patients with hepatocellular carcinoma, sepsis, and acute kidney injury. Its relevance to clinical outcomes in acute pancreatitis (AP) is not well defined. A retrospective multicenter analysis of critically ill patients with AP was conducted using the medical information mart for intensive care (MIMIC) IV (v3.1) and eICU collaborative research database (eICU-CRD) (v2.0) databases. The association between ALBI score and mortality was analyzed using Kaplan-Meier survival curves, smooth curve fitting, and both univariate and multivariate Cox regression analyses. A subgroup analysis was conducted to evaluate the robustness of the results. This study analyzed 529 AP patients from the MIMIC-IV database and 410 from the eICU-CRD database. ALBI scores were categorized into 2 groups: <-1.546 and ≥-1.546. The higher-ALBI-scores group was associated with higher in-hospital (adjusted hazard ratios [HRs]: 2.34, 95 % confidence intervals [CIs]: 1.45-3.79, P < .001) and intensive care unit mortality (adjusted, MIMIC-IV HR: 2.17, 95 % CI: 1.23-3.84, P = .008 vs eICU-CRD HR: 2.22, 95% CI: 1.08-4.56, P = .029) compared to the lower-ALBI-scores group. Curve-fitted analysis revealed a linear relationship between ALBI scores and mortality was observed (P for nonlinearity > .05). The ALBI score did not interact with most subgroups. In critically ill patients with AP, an elevated ALBI score is associated with worse clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.